Key regulators are not recommending Lilly’s Kisunla be cleared for the European market. The company says it plans to appeal ...

An expert panel of the EU drug regulator, the European Medicines Agency (EMA), on Friday declined to endorse Kisunla ...

After failing to pass muster with England’s drug reimbursement watchdog earlier this month, Eli Lilly’s Alzheimer’s disease ...

Eli Lilly has emerged as a popular growth stock thanks to its strength in the weight loss space. But the pharma giant also has an enormous opportunity in the Alzheimer's Disease market.

Oral semaglutide reduced risk for major adverse CV events by 14% in high-risk adults with type 2 diabetes regardless of SGLT2 ...

The British pharmaceutical giant is working with the U.K. Dementia Research Institute to exploit a “natural randomization” ...

Q4 2024 Earnings Call Transcript March 27, 2025 Oxford Industries, Inc. beats earnings expectations. Reported EPS is $1.37, ...

see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to ...

He also recommends avoiding Eli Lilly (LLY), as its tremendous revenue growth is hard to repeat. To watch more expert insights and analysis on the latest market action, check out more Market ...

INDIANAPOLIS, March 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that preclinical data for agents targeting SMARCA2 (BRM) and multiple KRAS mutations will be ...

Eli Lilly and Company today announced that preclinical data for agents targeting SMARCA2 (BRM) and multiple KRAS mutations will be presented at the American Association for Cancer Research (AACR) ...